101 results about "Dysfunctional uterine bleeding" patented technology

The invention is directed to an intravaginal uterine artery occlusion device for treating uterine disorders such as fibroids, dysfunctional uterine bleeding, postpartum hemorrhage and the like. A occlusion device has a cervical receptacle or cap with an open distal end for receiving the patient's uterine cervix and an elongated shaft having a distal end secured to the closed proximal end of the cervical receptacle and an inner lumen extending to the distal end of the elongated shaft. The patient's uterine cervix is held within the interior of the receptacle by the application of a vacuum to the interior of the receptacle through the inner lumen of the shaft or otherwise, while the leading edge(s) of the cervical receptacle press against the patient's vaginal fornix to occlude an underlying or adjacent uterine artery. At least one blood flow sensor may be provided on the leading edge of the receptacle to aid in locating a uterine artery and to monitor blood flow through the located uterine artery.

An intrauterine system is disclosed for use in the treatment of dysfunctional uterine bleeding; menorraghia; dysmenorrhoea; endometriosis; uterine fibroids; climacteric complaints; osteoporosis; and urogenital atrophy. The system is formed by a frame defining an interior space for receipt of a deposit of a therapeutically effective dose of a biologically active compound. The frame has an open structure allowing access to a substantial part of an outer surface of the deposit, and the deposit has a rate controlling structure that controls a rate of release of the compound within the uterus. One or more retention elements are provided on the frame for retaining the frame within the uterus of a female mammal.

A progesterone receptor modulator of the structure is provided. Use of compositions containing this compound for contraception, hormone replacement therapy, treating hormone-dependent disease, synchronizing estrus, treating dysmenorrhea, treating dysfunctional uterine bleeding, inducing amenorrhea, or treating symptoms of premenstrual syndrome and premenstrual dysphoric disorder in a mammal are described.

Devices, systems and methods for occluding blood vessels include a deployable constrictor having opposed pressure-applying portions, a delivery shaft configured to intravaginally advance the constrictor to the patient's cervix, a location sensor configured to detect a blood vessel, a deployment member for deploying the constrictor about the patient's cervix, and optionally a guide. The constrictor has a first configuration to receive a cervix and a second configuration to apply pressure to the cervical area to occlude a uterine artery by compression from the pressure-applying members. The pressure-applying members may be released from the cervix after a limited therapeutically effective time. The constrictor is for treating uterine disorders and conditions which may be treated by occlusion of the uterine arteries, such as uterine fibroids, dysfunctional uterine bleeding, post-partum hemorrhage, and bleeding associated with caesarian sections.

Devices, systems and methods for temporarily reducing or abolishing blood flow by occluding blood vessels are provided. A blood vessel-occlusion device embodying features of the invention includes a deployable pressure-applying member with a location sensor, and an applicator. The location sensor is configured to detect a blood vessel, which may be occluded by compression from the pressure-applying member. A pressure-applying member may be released from the applicator, with blood-vessel compression maintained after release. The applicator is configured to engage a guide, such as a tenaculum, to aid in the placement and operation of the applicator. A pressure-applying member may also engage the guide. The invention finds use in, for example, treating uterine disorders and conditions which may be treated by occlusion of the uterine arteries, such as uterine fibroids, dysfunctional uterine bleeding, post-partum hemorrhage, and bleeding associated with caesarian section.

Devices, systems and methods for occluding blood vessels include a deployable constrictor having opposed pressure-applying portions, a delivery shaft configured to intravaginally advance the constrictor to the patient's cervix, a location sensor configured to detect a blood vessel, a deployment member for deploying the constrictor about the patient's cervix, and optionally a guide. The constrictor has a first configuration to receive a cervix and a second configuration to apply pressure to the cervical area to occlude a uterine artery by compression from the pressure-applying members. The pressure-applying members may be released from the cervix after a limited therapeutically effective time. The invention finds use in, for example, treating uterine disorders and conditions which may be treated by occlusion of the uterine arteries, such as uterine fibroids, dysfunctional uterine bleeding, post-partum hemorrhage, and bleeding associated with caesarian sections.

A dispenser including a first dispensing portion including one group of storage units for each of ten to twenty-eight days, and a second dispensing portion, including at least one storage unit for each of seventeen to thirty days. In the first dispensing portion, a first set includes a group of four storage units for each day, a second set includes a group of three storage units for each day, and a third set includes a group of two storage units for each day. The first dispensing portion contain a progestin. In the second dispensing portion, the first fourteen storage units contain a placebo and the remaining storage units contain a progestin. First and second dispensing portions may be provided as separate dispensing packs, or as a multi-pack of second dispensing portions. The dispenser is useful for treatment of acute episodes of dysfunctional uterine bleeding (DUB) and maintenance treatment for preventing future episodes of DUB.

An intrauterine system is disclosed for use in the treatment of dysfunctional uterine bleeding; menorraghia; dysmenorrhoea; endometriosis; uterine fibroids; climacteric complaints; osteoporosis; and urogenital atrophy. The system is formed by a frame defining an interior space for receipt of a deposit of a therapeutically effective dose of a biologically active compound. The frame has an open structure allowing access to a substantial part of an outer surface of the deposit, and the deposit has a rate controlling structure that controls a rate of release of the compound within the uterus. One or more retention elements are provided on the frame for retaining the frame within the uterus of a female mammal.

The invention discloses the application of astragalin in preparation of anti-ovarian-senescence medicaments. Astragalin can treat various ovarian failure diseases, and has a remarkable effect on polycystic ovarian syndrome, dysfunctional uterine bleeding, premature ovarian failure or climacteric syndrome and the like. According to the invention, astragalin is prepared into oral medicaments, percutaneous medicaments or parenteral medicaments for treating ovarian failure diseases.

The invention relates to an oral preparation of consolidating-yin decoction medicine, which is prepared with ginseng and other seven Chinese medicines mainly for treating yin deficiency and emission, turbid leucorrhea and dribbling and non-consolidation of menses resulted from deficiency, and the preparation method thereof. The oral preparation is prepared according to the conventional processes and utilizing the mixed extracts as raw materials, such as ginseng, old land, Chinese yam, cornus officinalis, dodder, milkwort, schisandra chinensis and baked licorice, together with vector or excipient which are utilized as matrix and acceptable in pharmacy. The preparation has the effects of reinforcing kidney and regulating menstruation, and mainly treats yin deficiency and frequent diarrhea, turbid leucorrhea and dribbling and non-consolidation of menses resulted from deficiency. The long-term clinical application of the prescription shows that the preparation has good effects on menoxenia, dysfunctional uterine bleeding, infertility, amenorrhea and nocturnal emission, etc.

The invention relates to C27 spirostane-type steroidal saponins isolated from Ypsilandra, Trillium and Paris and their preparation method, as well as their application in the preparation of drugs for treating hemorrhagic diseases, and application in the preparation of drugs for treating dysfunctional uterine bleeding, and the preparation of functional daily chemical products and health products. The materials used in a method of the invention are easy to obtain, the method is simple and easily operable, biological experiments of the compound produced show that the compound can induce platelet aggregation activity and hemostatic activity significantly.

The present invention relates to a traditional Chinese medicine preparation, especially a medicine for treating dysfunctional uterine bleeding, composed of the following raw materials: motherwort, codonopsis pilosula, sstragalus root, atractylodes macrocephala, panax notoginseng, fried Chinese angelica, radix paeoniae rubra, artemsia argyi, bupleurum root, carbonized sanguisorba root and glycyrrhiza. The traditional Chinese medicine preparation has no side effect, convenient administration, short treatment period and obvious curative effect.

The invention discloses application of a phenolic acid compounds in preparation of bleeding stopping and stasis eliminating medicaments. The phenolic acid compounds mainly comprise chlorogenic acid, caffeic acid, coumaricacid, vanillic acid, cinnamic acid, syringic acid, protocatechuric acid, gallic acid, ferulic acid, p-hydroxybenzoic acid, hydroquinone or pyrocatechol and medicinal salts thereof. Experiments show that the phenolic acid compounds have the functions of stopping blood and eliminating stasis; one or more of the active ingredients is applied to preparing the bleeding stopping and stasis eliminating medicaments which are used for preventing and treating menorrhagia, artificial abortion, postpartum hemorrhage and dysfunctional uterine bleeding of women.

The invention provides a traditional Chinese medicine preparation for treating kidney-yin deficiency-type dysfunctional uterine bleeding. The traditional Chinese medicine preparation comprises the following bulk drugs in parts by weight: 10-20 parts of siberian solomonseal rhizomes, 10-20 parts of white paeony roots, 10-20 parts of raspberries, 10-20 parts of astragalus membranaceus, 10-20 parts of dogwoods, 10-20 parts of radix asparagi, 10-20 parts of cyrtomium rhizome carbon, 10-20 parts of dried rehmannia, 10-20 parts of dwarf lilyturf tubers, 10-20 parts of corydalis tuber, 10-20 parts of motherworts, 10-20 parts of carbonized hair, 10-20 parts of Chinese angelica, 10-20 parts of trogopterus dung, 10-20 parts of cortex lycii radicis, 10-20 parts of polygala roots, 10-20 parts of rhizoma cyperi, 10-20 parts of Chinese magnoliavine fruits, 10-20 parts of poria cocos, 10-20 parts of hairyvein agrimony, 10-20 parts of fried sanguisorba, 10-20 parts of eclipta alba and 10-20 parts of rhizoma curculiginis. According to the traditional Chinese medicine preparation, the disease cause is solved by tonifying qi and nourishing yin and tonifying lung and kidney, the root cause is eliminated by soothing liver and strengthening spleen, and nourishing blood and smoothing nutrition qi, and the current problems are treated by strengthening thoroughfare and conception vessels and reinforcing main and collateral channels and stanching.

The invention relates to a traditional Chinese medicine combination for treating gynaecological hemorrhagic disease, belongs to the traditional Chinese medicine field. The invention is characterized in that the traditional Chinese medicine combination is made from raw ingredients by weight parts as follows: Prepared Nutgrass Galingale Rhizome is 8 to 25 parts, typha orientalis stir-fried with vinegar is 5 to 20 parts, Myrrha Preparata is 8 to 20 parts, panpax notoginseng is 3 to 15 parts, stir-frying bitter orange is 8 to 20 parts, leonurus japonicus is 8 to 25 parts, and agrimony is 8 to 25 parts. The invention has the efficacies of thoroughfare regulating as well as hemostasia, and blood stasis and detoxication dissolving. The traditional Chinese medicine combination is mainly used for dysfunctional uterine bleeding, blood menostaxis, excess menstrual blood, postpartum lochiorrhea, the uterine bleeding caused by curettage, intrauterine device and induced labor, hysteromyoma, and vaginal bleeding caused by cervical erosion. The traditional Chinese medicine combination can achieve hemostasia purpose on various syndromes of deficiency complicated with excess.

The present invention relates to a drug for treating dysfunctional uterine bleeding, the India madder root, Sanguis Draconis and carbonized human hair are mixed and smashed into the fine powder, the Chinese angelica, baical skullcap root, trogopterus dung, cattail pollen, south dodder seed etc. are boiled by water and then filtered and condensed into the thick paste, the drug powder is added for even mixing, finally the product is prepared by smashing and filling in the capsule. The drug of the present invention has the effects of nourishing blood, cooling blood, activating blood circulation, removing blood stasis and hemostasis, which is applicable to the treatment of the advanced menstruation of women, large amount of menstrual bleeding or large amount of uterine bleeding caused by contraceptive ring embedding and drug abortion and other diseases; the present invention has the advantages of easy administration, accurate efficacy and no toxicity or side effects etc. The total effective rate can reach 96.0 percent through the clinical efficacy observations of 100 cases of patients with dysfunctional uterine bleeding.

The invention relates to a traditional Chinese medicinal composition preparation for treating dysfunctional uterine bleeding and a preparation method thereof. The preparation method comprises the following steps of: mixing and crushing the following components in parts by weight: 15-25 parts of Chinese angelica, 15-25 parts of red peony root, 10-20 parts of sanguisorba officinalis, 25-35 parts of hairyvein agrimonia herb and bud, 10-20 parts of cirsium japonicum, 10-20 parts of bletilla striata, 25-35 parts of cuttlebone, 10-20 parts of madder, 25-35 parts of raw rehmannia, 5-15 parts of liquorice, 6-10 parts of pseudo-ginseng, 10-15 parts of peony tree root bark, 25-35 parts of Chinese yam and 15-25 parts of bighead atractylodes rhizome; refluxing for 1-2 hours with 75 percent ethanol which is 5-6 times the volume of the crushed components; filtering to obtain filtrate, and repeatedly refluxing and extracting the residues for 2-3 times; mixing the filtrates and recycling the ethanol; uniformly mixing the filtrates and concentrating to dense extract of which the relative density at 80 DEG C is tested to be 1.21-1.25, thus obtaining ointment; moving the ointment into an oven, baking at 50-70 DEG C until the moisture content is lower than 5 percent; grinding to obtain medicinal powder. The traditional Chinese medicinal composition enables monarch, minister, assistant and guide to play respective effects, can quickly take effect, hardly causes side effects, can be applied both internally and externally and can treat both symptoms and root causes. The traditional Chinese medicinal composition can quickly inhibit development of diseases and remarkably shorten the course of diseases and is remarkable in treatment effect and worthy of popularization and application.

The subject matter of the instant invention is pertinent to the field of hormone therapy. More specifically, the subject matter of the instant invention concerns methods of treating dysfunctional uterine bleeding. The instant invention is also relevant to the treatment and / or prevention of anemia in patients with dysfunctional uterine bleeding. Compositions for practicing the methods, comprising progesterone antagonists are also disclosed. Embodiments of the instant invention also disclose methods for identifying new selective progesterone receptor modulators for practicing disclosed methods of treatment.

The invention discloses a progesterone preparation composite and a preparation method thereof, belonging to the field of chemical medicine preparations. The progesterone preparation composite comprises a progesterone oil solution containing substance, the progesterone oil solution containing substance is prepared from the following components by every 1000 progesterone preparation composites: 2-30 grams of progesterone, 75-1000 grams of nonpolar solvents and 0-180 grams of solubilizers, wherein the nonpolar solvent is vegetable oil or / and animal oil; and the solubilizer is lecithin or / and beewax. The reached progesterone preparation composite can be used for oral administration, is 10 times higher than a commercial progesterone capsule in dissolution rate and bioavailability, has the advantages of small taking dosage, high bioavailability, little adverse reaction, and the like and can be used for various diseases or symptoms, i.e. threatened abortion, habitual abortion, artificial insemination, sterility, premenstrual tension syndromes, anovulatory dysfunctional uterine bleeding, anovulatory amenorrhoea, endometriosis, climacteric syndromes, and the like which are caused by insufficient progestational hormones or corpus luteum functions.

The invention discloses application of luteolin in preparation of ovarian senescence resistance medicines. The luteolin has obvious effects in treatment of multiple ovarian regression diseases such as polycystic ovarian syndrome, dysfunctional uterine bleeding, premature ovary failure or climacteric syndrome. The luteolin is prepared into oral medicines, transdermal delivery medicines or injection medicines for treating the ovarian regression diseases.

The invention discloses a medicine for treating dysfunctional uterine bleeding and a preparation method thereof. The medicine disclosed by the invention is prepared from the following medicines according to a certain weight ratio: codonopsis pilosula, astragalus membranaceus, scutellaria baicalensis, golden cypress, radix rehmanniae recen, radix paeoniae alba, sophora flower, garden burnet, pollen typhae, rhizoma cyperi, tortoise plastron, chrysanthemum, prepared rehmannia root, American ginseng, liquorice, moutan bark, Yunnan supplejack root and the like. The medicine disclosed by the invention has the functions of tonifying qi, consolidating, clearing heat, cooling blood, invigorating the circulation of blood, dispersing blood stasis, stopping bleeding and relieving desertion. For treating dysfunctional uterine bleeding, the medicine disclosed by the invention takes effect quickly, prevents recurrence of dysfunctional uterine bleeding and is high in curative rate.

The invention relates to a medicament for treating liver-kidney yin deficiency type anovulatory dysfunctional uterine bleeding, and a preparation method and application thereof. The medicament is prepared from the following raw material medicaments in part by weight: 190 to 290 parts of white paeony root, 270 to 370 parts of rehmannia root, 190 to 290 parts of yerbadetajo herb, 190 to 290 parts of glossy privet fruit, 190 to 290 parts of himalayan teasel root, 30 to 130 parts of donkey-hide glue, 190 to 290 parts of radix pseudo-ginseng, 430 to 530 parts of astragalus, 190 to 290 parts of cortex lycii radicis and 270 to 370 parts of cuttlebone. The preparation method comprises the following steps of: according to the weight part, adding alcohol into the white paeony root, the yerbadetajo herb, the glossy privet fruit, the himalayan teasel root, the radix pseudo-ginseng and the astragalus for reflux and extraction, filtering, recovering the alcohol from the alcohol extract under reduced pressure, and concentrating the alcohol extract until the alcohol extract has no alcohol odor so as to obtain alcohol extract concentrated solution and decoction dregs for later use; and merging the decoction dregs with radix rehmanniae praeparata, the cortex lycii radicis and the cuttlebone, decocting the mixture by using water, filtering decoction, concentrating filter liquor under reduced pressure, adding the alcohol into the concentrated filter liquor, uniformly stirring, standing, filtering, recovering the alcohol from the filter liquor to obtain concentrated solution of water extraction and alcohol precipitation, merging the concentrated solution of water extraction and alcohol precipitation with the alcohol extract concentrated solution, adding the molten donkey-hide glue into the mixture, concentrating and performing vacuum drying to prepare dry extract powder.

The invention provides a traditional Chinese medicine formula for treating climacteric dysfunctional uterine bleeding. The traditional Chinese medicine formula comprises, by weight, of 25-35 parts of verbena, 25-35 parts of pyrola, 12-18 parts of madder, 12-18 parts of leonurus, 12-18 parts of glossy privet fruit, 12-18 parts of eclipta alba, 12-18 parts of merremia sibirica, 8-10 parts of the root of rehmannia, 10-12 parts of the root bark of the peony tree, 4-5 parts of the stem of noble dendrobium, 6-8 parts of radix pseudostellariae, 8-10 parts of astragalus membranaceus, 8-10 parts of crinis trachycarpi, 8-10 parts of nepeta atroviridis, 8-10 parts of radix paeoniae alba, 8-10 parts of dogwood and 10-12 parts of parasitic loranthus. The traditional Chinese medicine formula has the effects of dispersing blood stasis, stopping bleeding, nourishing the liver and the kidney and tonifying Qi and blood at the same time, and the good treatment effect is achieved on treating the climacteric dysfunctional uterine bleeding.

The invention relates to a traditional Chinese medicine for treating dysfunctional uterine bleeding, which is characterized by comprising the following raw medicines in proportions by weight: 30-40g of crude milk vetch, 20-30g of dangshen, 15-20g of fried bighead atractylodes rhizome, 6-9g of skunk bugbane, 6-10g of roasted licorice, 9-12g of dried orange peel, 20-30g of madder, 20-30g of agrimony, 9-12g of crude cattail pollen and 9-12g of common cephalanoplos herb. The effective rate is 85%, and the cure rate is 64.5%.

The invention discloses an application of oxyresveratrol in preparing an ovary aging resistant medicine. The oxyresveratrol has significant treatment effects on various ovary aging diseases such as polycystic ovarian syndrome, dysfunctional uterine bleeding, premature ovarian failure and climacteric syndrome. The oxyresveratrol is prepared into the oral, transdermal or injection medicine for treating the ovary aging diseases.

A dispenser including a first dispensing portion including one group of storage units for each of ten to twenty-eight days, and a second dispensing portion, including at least one storage unit for each of seventeen to thirty days. In the first dispensing portion, a first set includes a group of four storage units for each day, a second set includes a group of three storage units for each day, and a third set includes a group of two storage units for each day. The first dispensing portion contain a progestin. In the second dispensing portion, the first fourteen storage units contain a placebo and the remaining storage units contain a progestin. First and second dispensing portions may be provided as separate dispensing packs, or as a multi-pack of second dispensing portions. The dispenser is useful for treatment of acute episodes of dysfunctional uterine bleeding (DUB) and maintenance treatment for preventing future episodes of DUB.

The invention discloses application of 5-hydroxymethylfurfural in the preparation of anti-ovarian senescence drugs. 5-Hydroxymethylfurfural can treat various ovarian failures significantly effectively, such as polycystic ovarian syndrome, dysfunctional uterine bleeding, premature ovarian failure or climacteric syndrome. The 5-hydroxymethylfurfural is made herein into oral drugs, transdermal drugs or injectable drugs for treating ovarian senescence.

The invention belongs to the technical field of medicines, and in particular relates to a traditional Chinese medicine preparation for treating dysfunctional uterine bleeding and a preparation method thereof. The traditional Chinese medicine preparation is prepared from the following raw materials: codonopsis pilosula, milkvetch root, white paeony root, India madder root, largetrifoliolious bugbane rhizome, Chinese angelica, roasted nutgrass galingale rhizome, yerbadetajo herb, panax notoginseng and glossy privet fruit. The traditional Chinese medicine preparation disclosed by the invention has the main effects of nourishing the liver and kidneys, invigorating qi and strengthening superficial body resistance, and nourishing blood and regulating menstruation, and has good treatment effects on symptoms such as menstrual volume, menstrual period, menstrual cycle and recent hemostasis.